- Home
- GLMD vs UPXI Comparison
GLMD vs UPXI Comparison
Compare GLMD & UPXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLMD
- UPXI
- Stock Information
- Founded
- GLMD 2000
- UPXI 2018
- Country
- GLMD Israel
- UPXI United States
- Employees
- GLMD N/A
- UPXI N/A
- Industry
- GLMD Biotechnology: Pharmaceutical Preparations
- UPXI Medicinal Chemicals and Botanical Products
- Sector
- GLMD Health Care
- UPXI Health Care
- Exchange
- GLMD Nasdaq
- UPXI Nasdaq
- Market Cap
- GLMD 4.6M
- UPXI 5.1M
- IPO Year
- GLMD 2014
- UPXI 2021
- Fundamental
- Price
- GLMD $3.03
- UPXI $3.95
- Analyst Decision
- GLMD
- UPXI Hold
- Analyst Count
- GLMD 0
- UPXI 1
- Target Price
- GLMD N/A
- UPXI $25.00
- AVG Volume (30 Days)
- GLMD 47.4K
- UPXI 108.5K
- Earning Date
- GLMD 01-03-2025
- UPXI 02-12-2025
- Dividend Yield
- GLMD N/A
- UPXI N/A
- EPS Growth
- GLMD N/A
- UPXI N/A
- EPS
- GLMD N/A
- UPXI N/A
- Revenue
- GLMD N/A
- UPXI $22,082,477.00
- Revenue This Year
- GLMD N/A
- UPXI $299.03
- Revenue Next Year
- GLMD N/A
- UPXI N/A
- P/E Ratio
- GLMD N/A
- UPXI N/A
- Revenue Growth
- GLMD N/A
- UPXI N/A
- 52 Week Low
- GLMD $2.56
- UPXI $2.17
- 52 Week High
- GLMD $23.80
- UPXI $33.00
- Technical
- Relative Strength Index (RSI)
- GLMD 49.41
- UPXI 41.38
- Support Level
- GLMD $2.81
- UPXI $3.98
- Resistance Level
- GLMD $3.35
- UPXI $7.30
- Average True Range (ATR)
- GLMD 0.27
- UPXI 0.80
- MACD
- GLMD 0.06
- UPXI -0.11
- Stochastic Oscillator
- GLMD 56.63
- UPXI 10.77
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
About UPXI Upexi Inc.
Upexi Inc is an innovator in aggregation, accelerating Amazon and eCommerce businesses by combining consumer data and vertical integration to scale brands in multiple industries, while lowering costs with a growing distribution network.